Orthopedic Bone Cement Market Size, Share & Trends Analysis Report By Product (Antibiotic-Loaded Bone Cement, Non-Antibiotic Bone Cement), By Applications (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others), By End Use, By Region, and Segment Forecasts - 2035

Opportunity

""Outpatient arthroplasty and emerging-market surgical expansion create new growth opportunities.""

Ambulatory Surgical Centers provide one of the clearest market opportunities as selected orthopedic procedures shift from traditional inpatient care toward shorter-stay environments. ASCs currently account for an estimated 12% of orthopedic bone cement demand within the supplied application structure, but their share is expected to increase as patient selection, anesthesia, pain management, surgical technique, and enhanced recovery improve. Many carefully selected primary arthroplasty patients can now leave the surgical facility within 24 hours. This transition creates demand for cementing systems optimized for workflow efficiency, predictable timing, compact storage, and standardized preparation. ASCs often operate with fewer personnel and tighter room turnover schedules than tertiary hospitals, so bone cement products that simplify mixing and delivery can provide operational value beyond material performance alone.

Asia-Pacific creates another substantial opportunity as access to orthopedic reconstruction increases. The region contains more than 4 billion people, including rapidly aging populations in China, Japan, South Korea, and other markets. India is simultaneously expanding private hospital infrastructure and joint replacement access. Asia-Pacific is estimated to expand at approximately 5.3% annually within the current market framework, outpacing mature regions. Local surgeon training, insurance penetration, hospital investment, and manufacturing localization are expected to increase the number of cemented arthroplasty procedures. Antibiotic-Loaded Bone Cement can be particularly relevant in complex revision environments, while Non-Antibiotic Bone Cement remains important for standard primary procedures where surgeons prefer conventional fixation without incorporated antimicrobial agents.

Challenge

""Maintaining mechanical performance while optimizing antibiotic delivery remains technically demanding.""

Antibiotic-Loaded Bone Cement creates a fundamental formulation challenge because the cement must provide structural fixation while also releasing an effective local antibiotic concentration. Adding too much antibiotic or altering powder composition can change polymerization behavior, mechanical strength, viscosity, and fatigue performance. Commercial formulations therefore use standardized antibiotic quantities. One contemporary 40-gram cement unit contains 1 gram of active gentamicin, while another high-viscosity antibiotic-loaded product contains 0.5 gram of active gentamicin. These controlled concentrations illustrate the narrow balance between antimicrobial functionality and cement performance. Surgeons sometimes customize antibiotic combinations during revision surgery, creating additional variability that manufacturers cannot completely control through factory-prepared products.

Handling consistency is another challenge because bone cement performance is time and temperature dependent. Polymerization begins after the powder and liquid components are combined, creating sequential mixing, waiting, application, and hardening phases. A delay of several minutes can materially change viscosity and handling behavior. Operating-room temperature, mixing method, cement quantity, and staff technique can all influence working time. Low-viscosity formulations provide different flow characteristics from high-viscosity products, and surgeons may require different cement behavior for hip, knee, spine, or other orthopedic applications. Vacuum mixing and cartridge delivery reduce variability, but successful outcomes still depend on coordinated execution by the entire surgical team.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Orthopedic Bone Cement Market is segmented by product type into Antibiotic-Loaded Bone Cement and Non-Antibiotic Bone Cement and by application into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others. Antibiotic-Loaded Bone Cement is estimated to account for approximately 58% market share, while Non-Antibiotic Bone Cement represents approximately 42%. Hospitals dominate application demand with approximately 71%, followed by Ambulatory Surgical Centers at 12%, Specialty Clinics at 10%, and Others at approximately 7%. The segmentation reflects the continued importance of complex hospital-based procedures while outpatient orthopedic surgery gradually expands the addressable market for standardized cementing technologies.

By Types

Antibiotic-Loaded Bone Cement: Antibiotic-Loaded Bone Cement holds approximately 58% market share and is widely used in selected revision arthroplasty, infection-management, and high-risk fixation procedures. Commercial formulations commonly incorporate gentamicin because of its broad antibacterial activity and compatibility with polymethyl methacrylate cement systems. One reduced-viscosity product contains 1 gram of active gentamicin in each 40-gram cement unit and is designed to generate high local antibiotic concentrations over several days. Another high-viscosity formulation contains 0.5 gram of active gentamicin and can be mixed manually or within a vacuum system. Demand remains particularly strong in revision knee and hip procedures, where surgeons may need both implant fixation and localized antimicrobial support. Clinical evidence is encouraging more selective use rather than indiscriminate prophylaxis in every primary procedure, increasing the importance of patient and procedure stratification.

Non-Antibiotic Bone Cement: Non-Antibiotic Bone Cement accounts for approximately 42% market share and remains widely used for primary arthroplasty and other procedures where antimicrobial incorporation is not considered necessary. High-viscosity formulations provide short waiting phases and longer application periods, while reduced-viscosity materials can improve syringe filling and flow into selected anatomical areas. Non-antibiotic cement also avoids unnecessary antibiotic exposure, making it an important option as hospitals strengthen antimicrobial stewardship. Contemporary cement products conform to standardized mechanical and material specifications and are available with radiopaque components to support postoperative imaging. Competition within this segment centers on viscosity, fatigue strength, handling predictability, mixing efficiency, working time, and compatibility with modern cementing systems.

By Applications

Hospitals: Hospitals account for approximately 71% market share because they perform the majority of complex primary arthroplasty, revision reconstruction, trauma, infection treatment, and medically high-risk orthopedic procedures. A tertiary orthopedic hospital may perform hundreds or thousands of hip and knee replacements annually, generating recurring demand for cement and associated accessories. Revision cases require particularly sophisticated resources because surgeons may need implant extraction, spacer preparation, multiple cement units, and extended postoperative care. Large institutions also standardize cementing protocols through vacuum mixing, pulsatile lavage, cement guns, and pressurization systems. Hospital purchasing therefore increasingly evaluates the complete fixation workflow rather than only the price of one cement packet.

Ambulatory Surgical Centers (ASCs): Ambulatory Surgical Centers represent approximately 12% market share and are expected to gain importance as selected orthopedic procedures migrate to outpatient settings. Suitable patients undergoing uncomplicated joint replacement may be discharged within 24 hours, reducing reliance on conventional inpatient pathways. ASCs favor standardized products that reduce preparation variability and support rapid operating-room turnover. Cement systems with predictable working phases, compact mixing devices, and straightforward delivery can therefore provide significant workflow advantages. Growth remains dependent on reimbursement, patient selection, surgeon comfort, and the ability to manage unexpected complications without prolonged hospitalization.

Specialty Clinics: Specialty Clinics account for approximately 10% market share and include dedicated orthopedic facilities offering focused musculoskeletal procedures. These centers may perform primary joint replacement, selected trauma surgery, vertebral procedures, and other interventions requiring cemented fixation. Compared with large hospitals, specialty facilities often operate smaller surgical teams and fewer operating rooms, making efficiency particularly important. A center performing 5 orthopedic procedures per day can substantially reduce cumulative room time when cement preparation becomes more standardized. Specialty Clinics are also increasingly connected with physician-owned orthopedic networks that combine consultation, imaging, surgery, rehabilitation, and follow-up within coordinated care pathways.

Others: Others represent approximately 7% market share and include orthopedic cement utilization outside the primary supplied institutional categories. Demand can involve training facilities, specialized surgical environments, and other musculoskeletal procedures requiring acrylic cement fixation or stabilization. The category remains smaller because major arthroplasty volumes are concentrated in Hospitals and ASCs. Nevertheless, growth in specialized orthopedic services is increasing use of different cement viscosities and delivery systems. Manufacturers serving this segment benefit from broad portfolios because one customer may require both antibiotic-loaded and non-antibiotic formulations across several procedure types.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 39% of the Orthopedic Bone Cement Market, supported by large arthroplasty volumes, high healthcare spending, established orthopedic hospital networks, and extensive use of modern fixation technologies. The United States forms the majority of regional demand. A major national registry surpassed 4 million captured hip and knee arthroplasty procedures during 2024, while its annual analysis included more than 3.7 million procedures submitted from 1,447 institutions. These volumes provide a substantial recurring base for cemented fixation, revision surgery, infection management, and cementing accessories.

The regional market is also changing as orthopedic procedures shift into Ambulatory Surgical Centers. Hospitals remain dominant, but outpatient joint replacement is expanding among carefully selected patients. North America has also been at the center of debate around antibiotic-loaded cement utilization, with recent analyses evaluating millions of arthroplasty cases. The resulting focus on evidence-based antibiotic use is likely to favor differentiated portfolios offering both antibiotic-loaded and non-antibiotic options. Market growth will also be supported by revision requirements as a large installed base of existing implants ages over periods exceeding 10 to 20 years.

Europe

Europe represents approximately 29% of global market demand and has a deeply established tradition of cemented orthopedic fixation. Scandinavian and other European joint registries have provided long-term outcome information on cemented arthroplasty extending beyond 10 years, supporting continued surgeon familiarity with standardized cementing techniques. Germany, the United Kingdom, France, Italy, Spain, the Nordic countries, and other markets maintain substantial joint replacement volumes. Antibiotic-loaded cement is widely established in several European arthroplasty pathways, although utilization patterns vary by country and clinical indication.

European demand is increasingly shaped by aging populations and antimicrobial stewardship. The region has extensive revision arthroplasty infrastructure and substantial adoption of standardized bone-bed preparation, vacuum mixing, delivery, and pressurization techniques. Regulatory and clinical scrutiny is encouraging hospitals to distinguish between primary and revision use of antibiotic-loaded formulations. Recent evidence reviewing 10 meta-analyses has intensified discussion around routine prophylactic antibiotic cement, while established infection-treatment pathways continue to support demand in selected revision procedures. Europe is therefore likely to maintain a balanced portfolio between Antibiotic-Loaded Bone Cement and Non-Antibiotic Bone Cement.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 25% market share and is projected to record the fastest expansion at around 5.3% annually. China, India, Japan, South Korea, Australia, and Southeast Asia are expanding orthopedic surgical capacity as aging populations and rising healthcare access increase joint-replacement demand. Japan already has an advanced orthopedic system, while China and India provide larger long-term volume opportunities because of their population scale. Rising private insurance and hospital investment are allowing more patients to access procedures that were previously concentrated among higher-income urban groups.

The region also offers manufacturing and distribution opportunities because hospitals require affordable cement solutions alongside premium orthopedic implants. Cemented fixation remains clinically relevant where patients present with poorer bone quality or where surgeons prefer immediate mechanical stability. Asia-Pacific's population exceeds 4 billion people, meaning even modest increases in arthroplasty penetration can create substantial demand. Surgeon education and standardized cementing technique will be important because product performance depends on procedural execution as well as material properties. Local production and regional distribution networks can also reduce supply constraints for high-volume hospital systems.

Middle East & Africa

Middle East & Africa accounts for approximately 7% of market demand and presents a developing orthopedic opportunity. Gulf countries are investing in tertiary hospitals, orthopedic specialty centers, and medical tourism, creating demand for modern joint replacement technologies. Aging expatriate and local populations are increasing requirements for hip and knee procedures, while higher-income health systems are adopting premium cementing and revision technologies. Hospitals remain the principal application because advanced arthroplasty remains concentrated in large institutional facilities.

Africa has a different market profile, with limited arthroplasty access outside major cities but substantial long-term need. More than 1.5 billion people live across the continent in the mid-2020s, creating a large future orthopedic patient population as healthcare systems develop. Affordability and reliable distribution remain more important than highly specialized product differentiation in many markets. Non-Antibiotic Bone Cement may provide a lower-complexity option for standard procedures, while Antibiotic-Loaded Bone Cement is important in selected revision and infection-related cases.

List of Top Orthopedic Bone Cement Companies

• Stryker Corporation
• Zimmer Biomet
• DePuy Synthes
• Smith & Nephew, Inc.
• DJO Global
• Aegis Spine
• Alphatec Spine
• Becton Dickinson
• Cook Medical
• Elite Surgical
• Evolutis
• Exactech

Top 2 Companies Market Share

Zimmer Biomet: Zimmer Biomet is estimated to hold approximately 19% share within the supplied competitive framework, supported by a broad portfolio of antibiotic-loaded and non-antibiotic cements, vacuum mixing systems, delivery components, pressurization tools, and cement spacer solutions. Its current portfolio includes high-viscosity and reduced-viscosity formulations, including products containing 0.5 gram or 1 gram of active gentamicin depending on the specific cement configuration. The company's positioning is strengthened by a complete Modern Cementing Technique approach spanning preparation, mixing, application, and implant fixation.

Stryker Corporation: Stryker Corporation is estimated to account for approximately 17% share within the same competitive framework, giving the top 2 suppliers a combined estimated share of approximately 36%. The company has an established presence in orthopedic fixation, joint replacement, trauma, surgical equipment, and cement-related technologies. Its broad operating-room portfolio creates cross-selling opportunities because hospitals increasingly procure cement within larger orthopedic ecosystems. Continued expansion of robotic and digital joint replacement workflows also gives the company access to high-volume arthroplasty customers that consume cemented and cementless fixation products according to patient requirements.

Investment Analysis

Investment in orthopedic bone cement increasingly focuses on standardized delivery systems, antimicrobial functionality, surgeon workflow, and manufacturing reliability rather than basic PMMA chemistry alone. A hospital may require bone preparation, vacuum mixing, cartridges, cement guns, nozzles, pressurization components, and 1 or more cement units for a single complex arthroplasty. Suppliers able to bundle these components can capture a larger proportion of procedural spending and improve standardization. Antibiotic-Loaded Bone Cement, representing approximately 58% of the market structure, remains an important investment area, but clinical evidence is encouraging more precise targeting toward revision and higher-risk applications. Product development must therefore emphasize validated antibiotic release and mechanical integrity rather than simply increasing antimicrobial concentration.

Asia-Pacific and outpatient orthopedic care provide additional investment opportunities. Regional growth near 5.3% annually supports localized manufacturing, distribution, and surgeon training, while ASCs represent approximately 12% of current application demand with potential for expansion. Manufacturers are likely to invest in cement products optimized for efficient mixing and predictable working times because outpatient centers place high value on operating-room turnover. Digital arthroplasty and robotic surgery also create indirect investment opportunities. Even though robotic systems do not inherently require cement, they increase standardization of bone preparation and implant positioning, allowing manufacturers to integrate cementing workflows into broader technology-driven orthopedic platforms.

New Product Development

New product development is concentrating on improved viscosity control, antibiotic delivery, mixing consistency, and visualization. High-viscosity cement provides a relatively short waiting phase followed by a longer working period, while reduced-viscosity products can improve flow and syringe delivery. Antibiotic-loaded formulations increasingly use factory-controlled quantities such as 0.5 gram or 1 gram of active gentamicin per cement unit to provide reproducible material characteristics. Radiopaque additives support postoperative visualization, while selected products include coloration that makes cement easier to distinguish from surrounding tissue during surgery. These developments improve handling without fundamentally changing the established PMMA fixation mechanism.

Innovation is also moving toward integrated cementing systems rather than isolated materials. Vacuum mixers improve preparation consistency, while preconfigured cartridges and delivery systems reduce manual transfers between mixing and application. Spacer molds provide another development pathway for two-stage revision procedures by allowing surgeons to create temporary antibiotic-loaded constructs in standardized geometries. At the same time, orthopedic companies continue developing cementless fixation and biologic alternatives, forcing cement manufacturers to improve procedural efficiency. The strongest future products are therefore likely to combine at least 3 benefits, such as predictable handling, reproducible mechanical properties, and compatibility with streamlined operating-room workflows.

Five Recent Developments

• May 2026: DePuy Synthes entered an exclusive distribution arrangement covering the United States, Canada, and Australia for an advanced bone graft substitute, extending its orthopedic biomaterials strategy across 3 major markets and reinforcing competitive investment in alternative and complementary bone-healing technologies.
• October 2025: A major global healthcare company announced plans to establish DePuy Synthes as a standalone orthopedics business. The planned organization is positioned to serve approximately 7 million patients annually and focus more directly on joint reconstruction, trauma, spine, and related musculoskeletal technologies.
• September 2025: A register-based analysis evaluated Antibiotic-Loaded Bone Cement among high-risk knee arthroplasty patients across multiple national joint registries, strengthening industry focus on evidence-based patient selection rather than universal antibiotic cement use in every primary procedure.
• April 2025: An umbrella review synthesized 10 previous meta-analyses examining Antibiotic-Loaded Bone Cement and periprosthetic joint infection prevention, highlighting differences between deep infection, revision outcomes, and total infection results and reinforcing demand for higher-quality clinical evidence.
• November 2024: A major U.S. joint replacement registry reported that its database had exceeded 4 million captured hip and knee arthroplasty procedures, with the annual analysis reviewing more than 3.7 million procedures from 1,447 institutions and recording 18% growth in captured procedures.

Report Coverage

The Orthopedic Bone Cement Market report evaluates industry conditions across the 2026-2035 forecast period using 2025 as the principal benchmark. Coverage includes the supplied product types Antibiotic-Loaded Bone Cement and Non-Antibiotic Bone Cement and the applications Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others. Antibiotic-Loaded Bone Cement is estimated to account for approximately 58% of product demand, while Non-Antibiotic Bone Cement represents approximately 42%. Hospitals hold approximately 71% of application demand, Ambulatory Surgical Centers 12%, Specialty Clinics 10%, and Others 7%. 

The competitive assessment covers Stryker Corporation, Zimmer Biomet, DePuy Synthes, Smith & Nephew, Inc., DJO Global, Aegis Spine, Alphatec Spine, Becton Dickinson, Cook Medical, Elite Surgical, Evolutis, and Exactech, with the duplicated DePuy Synthes input consolidated into one company entry. Current market analysis considers a U.S. registry exceeding 4 million captured hip and knee arthroplasties, annual procedural growth of approximately 18% within the latest major registry reporting cycle, antibiotic cement formulations containing between 0.5 gram and 1 gram of active gentamicin in selected commercial products, and modern cementing workflows incorporating more than 4 preparation and delivery stages. Coverage further evaluates arthroplasty demand, infection-management strategies, antibiotic stewardship, cementless competition, outpatient surgery, revision procedures, viscosity innovation, vacuum mixing, investment activity, regional adoption, and product-development priorities through 2035.